Finance

Lists
CYTK:NASDAQ
Cytokinetics, Inc.
၆၂.၉၁ US$
+၁.၄၅%
(+၀.၉၀) 1D
၆၂.၉၁ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Open
၆၁.၈၇ US$
High
၆၃.၀၃ US$
Low
၆၁.၅၉ US$
Mkt. cap
၈၇၄.၆၀ ဋေ
Avg. vol.
၂.၂၄ သန်း
Volume
၁.၁၂ သန်း
52-wk high
၈၈.၃၁ US$
52-wk low
၅၄.၃၀ US$
EPS
-၇.၂၂ US$
Beta
၀.၄၁
Shares outstanding
၁၃.၉၀ ကုဋေ
No. of employees
၆၇၃
Open
၆၁.၈၇ US$
High
၆၃.၀၃ US$
Low
၆၁.၅၉ US$
Mkt. cap
၈၇၄.၆၀ ဋေ
Avg. vol.
၂.၂၄ သန်း
Volume
၁.၁၂ သန်း
52-wk high
၈၈.၃၁ US$
52-wk low
၅၄.၃၀ US$
EPS
-၇.၂၂ US$
Beta
၀.၄၁
Shares outstanding
၁၃.၉၀ ကုဋေ
No. of employees
၆၇၃
News stories
From web sources and news partners
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၅ နာရီ
Cytokinetics EVP Fady Malik sells $214,830 in company stock
Investing.com Nigeria
Investing.com Nigeria
·
ပြီးခဲ့သည့် ၅ နာရီ
Form 4 Cytokinetics Inc For: 11 October By Investing.com
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees၆၇၃
Founded၁၉၉၇
HeadquartersSouth San Francisco, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to CYTK in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current ၆၂.၉၁ US$
၁၄၆.၀၀ US$ (+၁၃၂.၀၈%)
Average
၁၁၀.၃၃ US$ (+၇၅.၃၈%)
Lowest
၈၅.၀၀ US$ (+၃၅.၁၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Buy
Maintained
၁၁၃.၀၀ US$
+၇၉.၆%
10/08/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
၁၄၀.၀၀ US$
+၁၂၂.၅%
10/05/2026
Serge Belanger
Needham
Buy
Maintained
၁၁၂.၀၀ US$
+၇၈%
10/05/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
၁၀၅.၀၀ US$
+၆၆.၉%
10/02/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
၁၁၂.၀၀ US$
+၇၈%
09/01/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
၁၀၀.၀၀ US$
+၅၉%
08/31/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
၈၅.၀၀ US$
+၃၅.၁%
08/31/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
၁၀၅.၀၀ US$
+၆၆.၉%
08/28/2026
Emily Field
Barclays
Buy
Reiterated
၁၁၀.၀၀ US$
+၇၄.၉%
08/26/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
၁၀၇.၀၀ US$
+၇၀.၁%
08/07/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
၁၀၈.၀၀ US$
+၇၁.၇%
08/07/2026
Jason Butler
Citizens JMP
Buy
Maintained
၁၁၀.၀၀ US$
+၇၄.၉%
08/07/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
၁၄၆.၀၀ US$
+၁၃၂.၁%
07/31/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
၁၀၃.၀၀ US$
+၆၃.၇%
07/23/2026
Eric Joseph
Citi
Buy
Maintained
၉၉.၀၀ US$
+၅၇.၄%
07/16/2026
Ashwani Verma
UBS
Buy
Upgraded
၁၁၅.၀၀ US$
+၈၂.၈%
06/29/2026
Salim Syed
Mizuho Securities
Buy
Maintained
၁၁၈.၀၀ US$
+၈၇.၆%
06/23/2026
Unknown Analyst
Citi
Buy
Initiated
၉၉.၀၀ US$
+၅၇.၄%
05/19/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
05/06/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
-
-
02/25/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
-၁.၅၀ US$ / -၁.၆၀ US$
+၆.၃၀%beat
Revenue / Est. (USD)
၂.၈၆ ကုဋေ / ၁.၈၀ ကုဋေ
+၅၉.၄၆%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၁.၉၄ သန်း
၁.၇၈ ကုဋေ
၁.၉၄ ကုဋေ
၂.၈၆ ကုဋေ
Cost of goods sold
၉.၉၂ ကုဋေ
၁၀.၄၄ ကုဋေ
၉.၈၁ ကုဋေ
၁၀.၃၄ ကုဋေ
Cost of revenue
၉.၉၂ ကုဋေ
၁၀.၄၄ ကုဋေ
၉.၈၁ ကုဋေ
၁၀.၃၄ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၆.၉၅ ကုဋေ
၉.၁၇ ကုဋေ
၁၀.၄၉ ကုဋေ
၁၀.၄၄ ကုဋေ
Operating expense
၆.၉၅ ကုဋေ
၉.၁၇ ကုဋေ
၁၀.၄၉ ကုဋေ
၁၀.၄၄ ကုဋေ
Total operating expenses
၁၆.၈၇ ကုဋေ
၁၉.၆၁ ကုဋေ
၂၀.၃၀ ကုဋေ
၂၀.၇၈ ကုဋေ
Operating income
-၁၆.၆၈ ကုဋေ
-၁၇.၈၄ ကုဋေ
-၁၈.၃၆ ကုဋေ
-၁၇.၉၂ ကုဋေ
Other non operating income
-၂.၁၀ သန်း
၁.၄၂ ကုဋေ
-၁.၀၀ သိန်း
၁.၃၀ သန်း
EBT including unusual items
-၃၀.၆၂ ကုဋေ
-၁၈.၃၀ ကုဋေ
-၂၀.၆၀ ကုဋေ
-၁၉.၈၈ ကုဋေ
EBT excluding unusual items
-၁၈.၄၉ ကုဋေ
-၁၈.၃၀ ကုဋေ
-၂၀.၆၀ ကုဋေ
-၁၉.၈၈ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၃၀.၆၂ ကုဋေ
-၁၈.၃၀ ကုဋေ
-၂၀.၆၀ ကုဋေ
-၁၉.၈၈ ကုဋေ
Net profit margin
-၁၅,၈၁၄.၉၈%
-၁,၀၃၀.၈၇%
-၁,၀၆၄.၄၈%
-၆၉၄.၃၉%
Earnings per share
-၁.၅၄
-၁.၅၀
-၁.၆၇
-၁.၅၀
Interest and investment income
၁.၀၂ ကုဋေ
၁.၁၅ ကုဋေ
၁.၁၀ ကုဋေ
၁.၃၉ ကုဋေ
Interest expense
-၂.၆၃ ကုဋေ
-၃.၀၃ ကုဋေ
-၃.၃၃ ကုဋေ
-၃.၄၈ ကုဋေ
Net interest expenses
-၁.၆၁ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၃ ကုဋေ
-၂.၀၉ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁၆.၄၁ ကုဋေ
-၁၇.၅၅ ကုဋေ
-၁၈.၀၂ ကုဋေ
-၁၇.၅၅ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ